|Awarded On||August 20, 2014|
|Title||Mutant KRAS Reprograms Lipid Metabolism Exposing Beta- Oxidation as a Novel Therapeutic Target in Lung Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||John Minna|
|Cancer Sites||Lung and Bronchus|
Lung cancer is the leading cause of cancer-related death inTexas. This cancer type is often diagnosed in an advanced stage and is resistant to conventional therapy. As a result, the long-term survival of cancer patients is dismal. The KRAS oncogene is mutated in ~30% of non-small cell lung cancers, the most common form of this disease. The presence of mutant KRAS is associated with aggressive disease, poor outcome and an overall survival of about 15%. To make progress towards the generation of new therapies, we performed experiments to identify the cellular networks that cancer cells use to generate energy and building blocks. Our preliminary experiments indicate that mutant KRAS lung cancer...